Up-and-down immunity of pregnancy in humans [version 1; peer review: 2 approved]

Philippe Le Bouteiller ID, Armand Bensussan ID

INSERM U976, Université Paris Diderot, Sorbonne Paris Cité, Hôpital Saint-Louis, Equerre Bazin, 1, Avenue Claude Vellefaux, 75475 Paris Cedex 10, France

Abstract

One part of the human placenta in early pregnancy is particularly important for local immunity: the decidua basalis, which is transformed endometrium located at the site of embryo implantation. This placental bed tissue contains both maternal uterine immune cells, including decidual natural killer (NK) cells, the dominant leukocyte population exhibiting a unique phenotype, and fetal extravillous trophoblast which comes into direct contact with maternal decidual cells. To establish a successful placentation development and healthy pregnancy outcome, the maternal immune system must tolerate paternal antigens expressed by trophoblast cells yet remain efficient for clearing any local pathogen infection. This review deals mainly with decidual NK cells. A key element, among others, to achieve such dual functions is the direct interaction between activating and inhibitory receptors expressed by decidual NK cells and their specific ligands presented by trophoblast or other decidual cells. Depending whether maternal decidual cells and trophoblast are infected by viruses, the balance between activating and inhibitory receptor signals mediated by decidual NK cell–trophoblast cross-talk results in tolerance (healthy pregnancy) or specific killing (pathogen-infected cells).

Keywords

decidua basalis, maternal immune system, immune tolerance
Introduction
The human placenta consists of two components—a fetal and a maternal one—that must interact successfully for a healthy pregnancy outcome. The maternal component is the endometrium, which undergoes modifications to form the decidua basalis from the very earliest stages of pregnancy. The only fetal component is the trophoblast in contact with maternal immune cells, constituting the junction between two immunologically distinct individuals (mother and fetus). A recent report has developed a thorough classification system based on specific markers to identify the different trophoblast subpopulations in the first trimester of pregnancy. Invasive extravillous cytotrophoblast (EVCT) is present in the decidua basalis. Differing from the decidua basalis, the decidua parietalis lines the uterine cavity and is in direct contact with HL-A-G+ trophoblast in the chorion laeve with no invasion in spiral arteries. EVCT is also present in the distal ends of spiral arteries in contact with maternal blood, contributing to the uterine vascular remodeling. This remodeling is critical to ensure optimal utero-placental blood flow during pregnancy. In early pregnancy decidua, EVCT comes into close contact with various maternal immune cells: prominent granulated decidual natural killer (dNK) cells, macrophages, CD4+ T cells, including T helper 1 (Th1) cells, and CD8+ T cells. Another maternal-fetal interface is constituted by the multinucleated syncytiotrophoblast, the outer part of chorionic villi, which is in contact with maternal immune cells present in the maternal blood of the intervillous blood space. This review focuses mostly on the role of EVCT and dNK cells in pregnancy immunity.

During pregnancy, the maternal immune system responds to fetal trophoblast antigens. In particular, it produces maternal anti-paternal antibodies, but oddly these antibodies are not harmful for the fetus. Furthermore, in normal pregnancy, trophoblast is never destroyed by maternal decidual immune cells, suggesting the occurrence of very efficient immunosuppressive mechanisms. Yet recent findings demonstrate that viral infection awakens maternal decidual immunity to rapidly clear pathogens and avoid further spreading to the fetus. These intriguing, contradictory observations raise the following question: how do the interactions between maternal immune cells and fetal trophoblast either lead to downregulation of maternal anti-paternal immunity or trigger efficient maternal immunity against decidual pathogen-infected cells? The aim of this review is to analyze some of the recent scientific advances that contribute to explain these intriguing, contradictory observations. One key element of such up-and-down local decidual immunity lies in the specific receptor-ligand interactions occurring at the cell surface of maternal decidual immune cells and fetal trophoblast. Among the different control mechanisms described to date, the crucial role exerted by dNK cells in both healthy and virus-infected pregnancies will be the focus of this review.

Healthy pregnancy: down-modulated adaptive and innate decidual immunity
Unique array of HLA class I molecules on trophoblast
In contrast to most somatic cells, infiltrating EVCT cells do not express the polymorphic T-cell ligands HLA-A and HLA-B class I nor do they express HLA class II molecules. The absence of polymorphic HLA-A and HLA-B expression thus limits fetal antigen presentation by non-infected EVCT to the maternal CD8+ cytotoxic T cells. Moreover, it has been shown that cytotoxic T cells in the decidua express less perforin and granzyme B than CD8+ T cells present in the peripheral blood (PB). This is one of the various mechanisms used by the fetus for avoiding killing by CD8+ T cells of the invading EVCT which plays a crucial role in uterine vascular remodeling and placental development. EVCT cells express the fetal polymorphic class I molecule, HL-A-C, only in the β2-microglobulin-associated form and at a high level. HL-A-C is the ligand of activating or inhibitory killer-cell immunoglobulin receptors (KIRs). Engagement of these inhibitory receptors by specific, and so far unknown, trophoblast ligands downregulates the cytotoxic function of dNK cells. In addition, EVCT expresses the non-polymorphic HLA-E, HL-A-G, and HL-A-F heterodimer inhibitory dNK cell receptor (see next section). HL-A-G molecules are expressed at the cell surface of EVCT with a prolonged half-life. HL-A-G is the ligand of LILRB1 inhibitory receptor present on about 40% of dNK cells. LILRB1 has a high affinity for the dimeric form of HL-A-G on EVCT. Such strong binding contributes to limit the cytotoxic function of dNK cells. This is an additional inhibitory mechanism. Syncytiotrophoblast, the outer part of chorionic villi, in contact with the maternal blood of the intervillous space, is devoid of classical and non-classical HL-A class I surface expression. Thus, it cannot present fetal antigens to the maternal CD8+ T cells present in the intervillous space. Though a matter of debate, some reports indicate that syncytiotrophoblast produces soluble HL-A-G. Soluble HL-A-G might exert an immunosuppressive protective role in pregnancy by triggering the killing of maternal activated CD8+ T cells present in the decidua basalis as well as in the maternal blood of the intervillous space.

Decidual natural killer cells in healthy pregnancy: lack of cytotoxic function
dNK cells constitute the great majority of maternal immune cells present in early decidua basalis (about 70% of leukocytes present), where the EVCT infiltrates into maternal tissue. The dNK phenotype in healthy pregnancy is unique, differing from PB NK cells. The major dNK subpopulation is characterized as CD56bright/CD16−/CD160− (non-cytotoxic phenotype), whereas about 90% of the PB NK cells are CD56dim/CD16+/CD160+ (cytotoxic phenotype). Although their abundant intracellular lytic granules contain perforin, granzyme, and granulysin, dNK cells are poorly cytotoxic. In contrast to circulating NK cells, dNK cells display a poor ability to kill various non-infected cell target lines, including human K562 and P815 cell lines. Other dNK cell functions—regulation of trophoblast invasion and subsequent spiral artery remodeling—are controlled by dNK cell receptors that interact with specific HLA class I or non-major histocompatibility complex (non-MHC) class I ligands present on EVCT. Similarly, in mice, MHC molecules were shown to educate uterine NK cells to trigger uterine arterial remodeling. Although dNK cells express several activating receptors, including NKP46, NKP30, NKG2D, and CD94/NKG2C, and some activating receptors of the KIR family, they are not cytotoxic against EVCT. Several studies have characterized the
different mechanisms preventing the dNK cells from exerting cytotoxic function. First, this is due to specific interactions between dNK inhibitory receptors and specific ligands. We reported that the engagement of CD94/NKG2A inhibitory receptor with its specific ligand HLA-E expressed by EVCT is a dominant negative regulatory mechanism that prevents cytotoxicity toward trophoblast. Second, another inhibitory mechanism is provided by engagement of the LILRB1 inhibitory receptor by its specific HLA-G ligand expressed at the cell surface of EVCT. Third, a report demonstrated that VEGF-C secreted by dNK cells in the first trimester of pregnancy triggered upregulation of TAP-1 in EVCT, protecting them from a cytotoxic role. Thus, in normal pregnancy, there is an obvious resistance to dNK cell killing function, although dNK cells are potentially capable of cytolytic activity.

Pathogen-infected pregnancy: awakened decidual immunity

Contact with autologous decidual human cytomegalovirus-infected cells restores decidual natural killer cell killing potential

Human pregnancy is characterized by tolerance to the fetus through down-local decidual immunity but balanced with fetal decidual defense against pathogens. dNK cells are poorly cytotoxic in healthy pregnancy yet possess a likely functional lytic machinery. Indeed, using a redirected cell lysis assay, a study reported that specific engagement of Nkp46 and, to a lesser extent, Nkp30 activating receptors on isolated dNK cells from early decidua induced P815 cell target lysis. Human cytomegalovirus (HCMV) infection modulates the dNK cell receptor repertoire. Co-culture of dNK cells with HCMV-infected autologous stromal cells increased the number of CD56dim dNK cells associated with the appearance of CD16 and NKG2C activating receptors. Such a phenotype is consistent with the acquisition of a cytotoxic profile. Similarly, isolated dNK cells infected with Toxoplasma gondii were shown to express markers of cytotoxicity, including increased expression of CD16 and NKG2D receptors, and to acquire a CD56dim phenotype. These different observations indicated that dNK cells acquire cytotoxic potential in the pregnant uterus when the decidua is infected by pathogens. dNK cells become cytotoxic when in contact with HCMV-infected autologous decidual stromal cells. dNK cells engage immune synapse with HCMV-infected autologous stromal cells and polarize their lytic machinery toward infected cells. In contrast, purified dNK cells in contact with uninfected autologous stromal cells do not exert their killing function. Furthermore, via immunohistochemistry, the presence of dNK cells was observed in the vicinity of HCMV-positive cells in placental tissue obtained after elective pregnancy termination. Another article indicated that isolated dNK cells expressing KIR2DS1 activating receptor acquired higher cytotoxic function than KIR2DS1−/− dNK cells when in contact with HCMV-infected decidual stromal cells. Moreover, a recent study reported that a structural modulation of HLA-C is required for a potent KIR2DS1-mediated NK cell activation. Whether such HLA-C modulation could occur at the cell surface of HCMV-infected EVCT in pregnancy remains to be determined. Thus, dNK cells were shown to clearly exert a cytotoxic function in the pregnant uterus when the decidua is infected by pathogens.

A controversial question can legitimately arise from the above results obtained from in vitro co-culture of isolated dNK cells and stromal cells from the same early pregnancy sample: is there a bias due to the limited type of decidual cells surrounding dNK cells in these in vitro experiments? The beginning of an answer has been provided by a recent article. The authors used a multi-cell-type solid placental tissue containing a variety of immune and non-immune cells, including fetal and maternal cells which more closely resemble infection in vivo. In the latter study, it was demonstrated that HCMV infection triggered a robust interferon-gamma (IFN-γ) and IFN-γ-inducible protein-10 (IP-10) release by dNK cells, thus differing from another study that used in vitro co-culture with only two cell components: autologous dNK and decidual stromal cells. In the latter case, no upregulation of IFN-γ but rather down-modulation of IP-10 by dNK cells was observed. These different results demonstrate the crucial influence of the cellular microenvironment.

Decidual CD8+ T cells present in early pregnancy are fully functional. They can recognize fetal HLA-C expressed at high levels on the cell surface of EVCT. HLA-C expressed by EVCT thus exerts a dual role: it can present pathogen-derived peptides to decidual CD8+ T cells when EVCT is infected. HLA-C expressed by EVCT is also a specific ligand for various activating KIR dNK receptors. Such interactions result in the stimulation of dNK cell cytotoxic function. Whether virus-specific and HLA-C restricted decidual CD8+ T cells are present in infected decidua and able to kill infected cells remains to be determined. Detection of virus-specific CD8+ T cells in decidual tissue suggests that this might be the case. Moreover, a recent study demonstrated that activation of dNK cells through KIR2DS4 activating receptor (which also binds HLA-C) stimulates EVCT migration needed for subsequent placental development.

Concluding remarks

During pregnancy, there is a conflicting need for both reproductive success and protection against congenital transmission of viruses and other pathogens. To date, many mechanisms have been described that contribute to block potentially harmful maternal–anti-paternal immune response. Until recently, little was known about the ways used by the maternal immune system to eradicate local decidual infection. dNK cells present in large numbers in decidua basalis play different roles at the beginning of pregnancy by interacting with specific EVCT-bound ligands, including HLA class I. On the one hand, dNK cells are poorly cytotoxic, thus preventing the killing of EVCT. On the other hand, dNK cells acquire cytotoxic potential when they interact with infected decidual cells. Besides, the immunity of pregnancy requires the involvement of other limbs of the immune system. Indeed, several studies have identified additional mechanisms that contribute to T-cell tolerance in the decidua basalis. Several other innate and adaptive immune interactions occur at the maternal-fetal interface. Important to
consider is the role of regulatory T cells as well as Th17 cells in the human decidua. Whether the same dNK-mediated target recognition similarly blocks other viral congenital infections that may occur is yet to be elucidated. It would be important to study how local immunity in pregnancy may control infections of hepatitis C virus, human immunodeficiency virus, Zika virus, and T. gondii parasite.

### Competing interests
The authors declare that they have no competing interests.

###Grant information
The author(s) declared that no grants were involved in supporting this work.

###References


Open Peer Review

Current Peer Review Status: ✔ ✔

Editorial Note on the Review Process
F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1 Ana Claudia Zenclussen
   Experimental Obstetrics and Gynecology, Otto von Guericke University, Magdeburg, Magdeburg, Germany
   Competing Interests: No competing interests were disclosed.

2 Judith N Bulmer
   Reproductive and Vascular Biology Group, Institute of Cellular Medicine, Newcastle University, Newcastle, UK
   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com